The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Apr 10, 2024
0
35
A recent USC study provides new information about why SARS-CoV-2, the virus behind the COVID-19 pandemic, may elicit mild symptoms at first but then, for a subset of patients, turn potentially fatal a week or so after infection. ...
Mar 29, 2024
0
150
Chimeric antigen receptor T cells—CAR T cells for short—are immune cells (T cells) that are taken from the body and genetically modified outside the body in the laboratory using transport vehicles for the genes to be transmitted ...
Mar 22, 2024
0
32
In the ever-evolving battle against cancer, immunotherapy presents a turning point. It began with harnessing the body's immune system to fight cancer, a concept rooted more than a century ago but only gaining significant ...
Feb 21, 2024
0
63
Researchers from The University of Texas MD Anderson Cancer Center have reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived ...
Jan 18, 2024
0
76
Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes—and hope—to patients worldwide.
Jan 4, 2024
0
43
The Malaghan Institute of Medical Research, in collaboration with Wellington Zhaotai Therapies Limited, today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 chimeric antigen receptor ...
Dec 11, 2023
0
51
Survival outcomes using chimeric antigen receptor-T cell therapy (CAR-T cell therapy) continue to be impressive for patients with some blood cancers.
Sep 15, 2023
0
40
In recent years, cancer researchers have hailed the arrival of chimeric antigen receptor T cell (CAR T) therapy, which has delivered promising results, transforming the fight against various forms of cancer. The process involves ...
Sep 13, 2023
0
54
The inflammatory response is indispensable for protective immunity, yet microbial pathogens often trigger an excessive response, a "cytokine storm," harmful to the host. Despite recent advances in our understanding of inflammatory ...
Jul 19, 2023
0
45
